PE20230309A1 - Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos - Google Patents

Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos

Info

Publication number
PE20230309A1
PE20230309A1 PE2022002553A PE2022002553A PE20230309A1 PE 20230309 A1 PE20230309 A1 PE 20230309A1 PE 2022002553 A PE2022002553 A PE 2022002553A PE 2022002553 A PE2022002553 A PE 2022002553A PE 20230309 A1 PE20230309 A1 PE 20230309A1
Authority
PE
Peru
Prior art keywords
heteroaromatic
chemotherapy agents
macrocyclic ether
compounds
oxa
Prior art date
Application number
PE2022002553A
Other languages
English (en)
Inventor
Joshua Courtney Horan
Scot Richard Mente
Henry Efrem Pelish
Matthew D Shair
Xinxing Tang
Anupong Tangpeerachaikul
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of PE20230309A1 publication Critical patent/PE20230309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS ETERES MACROCICLICOS HETEROAROMATICOS DE FORMULA (I) DONDE Q, X, Y, Z, R1 Y R4 SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (20R)-3-ETIL-17-FLUORO-20-METIL-21-OXA-3,4,12,24- TETRAAZAPENTACICLO[20.3.1.0 2,6.0 8,13.0 14,19]HEXACOSA-1(25),2(6),4,8(13),9,11,14,16,18,22(26),23-UNDECAENO-23-AMINA; (19R)-11-ETIL-16-FLUORO-3,19-DIMETIL-20-OXA-3,4,10,11,23-PENTAAZAPENTACICLO[19.3.1.0 2,6.0 8,12.0 13,18]PENTACOSA-1(24),2(6),4,8(12),9,13,15,17,21(25),22-DECAENO-22-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS PROTOONCOGENES ROS1 y ALK SIENDO UTILES EN EL TRATAMIENTO DE CANCER.
PE2022002553A 2020-05-05 2021-05-05 Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos PE20230309A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088589 2020-05-05
US202063060331P 2020-08-03 2020-08-03
US202063125747P 2020-12-15 2020-12-15
PCT/US2021/030940 WO2021226269A1 (en) 2020-05-05 2021-05-05 Heteroaromatic macrocyclic ether chemotherapeutic agents

Publications (1)

Publication Number Publication Date
PE20230309A1 true PE20230309A1 (es) 2023-02-14

Family

ID=78468373

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002553A PE20230309A1 (es) 2020-05-05 2021-05-05 Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos

Country Status (12)

Country Link
US (2) US11667649B2 (es)
EP (1) EP4146205A4 (es)
JP (1) JP2023525040A (es)
KR (1) KR20230005987A (es)
AU (1) AU2021268345A1 (es)
BR (1) BR112022022530A2 (es)
CA (1) CA3179702A1 (es)
CL (1) CL2022003046A1 (es)
IL (1) IL297898A (es)
MX (1) MX2022013051A (es)
PE (1) PE20230309A1 (es)
WO (1) WO2021226269A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
PE20230309A1 (es) 2020-05-05 2023-02-14 Nuvalent Inc Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
WO2023179600A1 (zh) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
US20230322797A1 (en) * 2022-04-07 2023-10-12 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024074414A1 (en) * 2022-10-06 2024-04-11 Syngenta Crop Protection Ag Herbicidal imidazole compounds
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU2002217451B2 (en) 2000-12-20 2006-07-20 Kyowa Hakko Chemical Co., Ltd. Metal complex type squarylium compounds and optical recording media made by using the same
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004039859A1 (ja) 2002-10-30 2004-05-13 Sumitomo Chemical Company, Limited 高分子化合物およびそれを用いた高分子発光素子
US7446211B2 (en) 2004-04-27 2008-11-04 Wyeth Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
JP5031570B2 (ja) 2004-09-20 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 性ステロイドホルモン受容体モジュレーターとして有用な新規な四環式ヘテロ原子含有誘導体
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
WO2009000412A1 (en) 2007-06-26 2008-12-31 Sanofi Aventis A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
US8308996B2 (en) 2009-08-04 2012-11-13 Tokuyama Corporation Chromene compound
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
CA2774266A1 (en) 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
WO2012016147A2 (en) 2010-07-30 2012-02-02 Dr. Reddy's Laboratories Ltd. Ligands for selective asymmetric hydroformylation
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
EP2655344B1 (en) 2010-12-22 2015-11-25 Université Catholique de Louvain Novel phenazine derivatives and their use
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PT2658844T (pt) 2010-12-28 2017-01-24 Sanofi Sa Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
EP2669278B1 (en) 2011-01-27 2015-05-27 Tokuyama Corporation Chromene compound
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US9518217B2 (en) 2011-09-06 2016-12-13 E Ink Holdings Inc. Transition metal carbene complexes and the electroluminescent application thereof
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
JP6199752B2 (ja) 2013-01-24 2017-09-20 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子、並びに含窒素複素環化合物
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
WO2014207606A1 (en) 2013-06-28 2014-12-31 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
AU2015205327B2 (en) 2014-01-09 2019-02-14 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
EA201890421A1 (ru) 2015-08-03 2018-07-31 Бристол-Маерс Сквибб Компани Циклические соединения, пригодные в качестве модуляторов tnf-альфа
EP3374360A1 (en) 2015-11-13 2018-09-19 Mavalon Therapeutics Limited Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
ES2812336T3 (es) 2016-03-03 2021-03-16 Shenzhen Targetrx Inc Macrocíclico y composición que comprende el mismo
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
WO2019113071A1 (en) 2017-12-05 2019-06-13 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating alk-mediated cancer
CN111315721B (zh) 2017-12-21 2023-06-06 广州华睿光电材料有限公司 有机混合物及其在有机电子器件中的应用
WO2019149131A1 (zh) * 2018-01-30 2019-08-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
CN111356689B (zh) 2018-02-21 2023-11-10 株式会社Lg化学 化合物及包含其的有机发光器件
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
US11560399B2 (en) 2018-07-26 2023-01-24 Enterome Process for preparing mannose derivatives
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
CA3109686A1 (en) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders that target alk and therapeutic uses thereof
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN112533927A (zh) 2019-05-14 2021-03-19 苏州韬略生物科技有限公司 可用作激酶抑制剂的被取代的大环
CN114207861A (zh) 2019-08-02 2022-03-18 德山新勒克斯有限公司 有机电子器件
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
EP4079740A4 (en) 2019-12-16 2023-06-07 I-Sens, Inc. NEW TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIOSENSOR USING IT
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
PE20230309A1 (es) 2020-05-05 2023-02-14 Nuvalent Inc Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
CN115362155B (zh) 2020-07-22 2024-06-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用

Also Published As

Publication number Publication date
IL297898A (en) 2023-01-01
KR20230005987A (ko) 2023-01-10
BR112022022530A2 (pt) 2023-02-23
US20220098212A1 (en) 2022-03-31
WO2021226269A1 (en) 2021-11-11
JP2023525040A (ja) 2023-06-14
CL2022003046A1 (es) 2023-10-06
US20230076627A1 (en) 2023-03-09
EP4146205A4 (en) 2024-05-29
EP4146205A1 (en) 2023-03-15
MX2022013051A (es) 2023-01-24
AU2021268345A1 (en) 2022-11-10
US11667649B2 (en) 2023-06-06
US20220340586A9 (en) 2022-10-27
CA3179702A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
PE20230309A1 (es) Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
PE20191552A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3)
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
ECSP099803A (es) Derivados de bencimidazol
PE20090511A1 (es) Imidazopiridinonas
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
ECSP066997A (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
DOP2010000022A (es) Derivados de pirimidina 934
CL2008002798A1 (es) Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY30397A1 (es) Derivados sustituidos de la (3as, 7as)-1,3a,4,5,6,7-hexahidro-3h-benzoimidazol-2-ona, proceso de preparacion, composiciones conteniéndolos yaplicaciones
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones